Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
To enhance safety, existing guidance includes subcutaneous-only injections, limiting graft volume per session, experienced surgeons, ultrasound guidance in certain practices, and scrupulous patient selection
Among these, lipid-based nanocarriers have gained much attention due to their safety, stability, cost-effectiveness, high encapsulation efficiency, and suitability for surface brain targeting modification
RESEARCH AREAS Estrogen-related receptor alpha (ERR) agonism and receptor binding characterization Transcriptional regulation of mitochondrial biogenesis pathways (e.g., PGC-1 coactivation networks) Oxidative phosphorylation and fatty-acid oxidation gene-expression signaling Cellular energy-metabolism and substrate-utilization pathway modeling WHAT RESEARCHERS LOOK AT Receptor-binding and reporter-gene assays measuring ERR isoform engagement Dose-response transcriptional profiling of metabolic target genes in cell culture Mitochondrial density and respiration assays in isolated model systems Pathway-selectivity and off-target screening across nuclear-receptor panels QUICK SPECS Form: Capsule not for ingestion Net per capsule: 100mcg Count: 100 capsules per bottle Purity: 98% (HPLC) Identity: Confirmed by HPLC/MS Storage: Store sealed, cool, dry, protected from light IDENTITY BASICS Type: Synthetic small-molecule ERR agonist (non-peptide) Molecular formula: CHNO Molecular weight: ~445.5 g/mol CAS: 2231747-31-0 SELECTED RESEARCH PubChem: SLU-PP-332 compound record PubMed: SLU-PP-332 literature index PubMed: ERR agonist research PubMed: ERR/mitochondrial biogenesis signaling DISCLAIMER For laboratory and in vitro research use only
While Vafseo is now approved in 37 countries, the FDA did give the oral prolyl hydroxylase inhibitor a boxed warning over a heightened risk of death, stroke, myocardial infection, venous thromboembolism and thrombosis of vascular access
